Mystical experiences predict PTSD recovery after ibogaine, while psychedelic gene expression maps to human brain evolution
Two fascinating studies this week reveal how psychedelics work at both the mystical and molecular level—from predicting who recovers from PTSD to uncovering ancient genetic programs that shape consciousness.
🌟 Mystical Experiences Predict PTSD Recovery After Ibogaine
30 male veterans with traumatic brain injury received magnesium-ibogaine therapy and were assessed using the Mystical Experiences Questionnaire
Veterans reporting more intense mystical experiences showed dramatically larger reductions in PTSD symptoms both immediately after treatment (5.89-point greater improvement) and one month later (4.45-point greater improvement)
The mystical experience intensity also correlated with specific brain changes—greater reductions in peak alpha frequency, an EEG measure linked to ibogaine's therapeutic effects
Why it matters: This suggests that the subjective mystical experience during ibogaine treatment isn't just a side effect—it may be a key predictor of therapeutic success for PTSD recovery.
Key Findings
🧬 Psychedelic Genes Linked to Human Brain Evolution
Researchers mapped genes that respond to psychedelics across animal studies and cell cultures, then cross-referenced them with the Allen Human Brain Atlas to identify high-confidence psychedelic-responsive genes in humans
These genes were enriched in cortical pyramidal neurons (layers 5 and 6) and associated with neuron projection and spine morphology
Strikingly, psychedelic-responsive genes were overrepresented among human accelerated genes—genetic sequences that evolved rapidly during human evolution
🎯 Psilocybin Changes How We See Visual Context
Researchers used ultra-high field fMRI and the Ebbinghaus illusion (where circles appear different sizes based on surrounding context) to test psilocybin's effects on visual perception
Psilocybin altered both how people perceived contextual illusions and how their brains processed contextual visual information
A computational model successfully captured and linked these perceptual and neural changes
🔬 Psilocybin Matches Antidepressant for Emotional Processing
59 patients with moderate-to-severe depression were randomly assigned to receive either psilocybin (25mg twice) or escitalopram (daily for 6 weeks), both with psychological support
Both treatments equally reduced negative bias in facial emotion recognition compared to baseline
For escitalopram patients specifically, reduced misclassification of positive faces as negative was associated with lower depression scores at 1-month follow-up
🧪 Ketamine's Anti-Inflammatory Effects May Drive Antidepressant Action
Mice given lipopolysaccharide (LPS) to induce depression-like behavior were treated with ketamine (10-20 mg/kg)
Ketamine reduced despair and anhedonia while decreasing brain inflammation—specifically reducing neutrophils, dampening microglial activation, and blocking monocyte infiltration into the brain
In the spleen, ketamine increased anti-inflammatory immune cells and polarized macrophages toward an M2 phenotype
💊 Computer Models Test Psychedelics for Consciousness Disorders
Researchers created individualized brain models for patients with disorders of consciousness and simulated LSD and psilocybin administration
The simulated psychedelics shifted brain activity closer to criticality (the sweet spot between order and chaos) with greater effects in minimally conscious patients than unresponsive ones
Treatment response correlated with structural brain connectivity in unresponsive patients but with functional connectivity in minimally conscious patients
⚠️ Psychedelics During Pregnancy Disrupt Mouse Brain Development
Pregnant mice given LSD (0.3 mg/kg) showed the drug crossing the placenta and appearing in embryonic brain fluid within minutes
A single exposure at embryonic day 12.5 altered brain layer organization, while repeated dosing increased male-biased shifts in neuron types and microglia
Adult offspring showed reduced prepulse inhibition (a measure of sensory filtering) and increased repetitive behaviors, particularly in males
Implications
These studies reveal psychedelics work through multiple pathways—from mystical experiences that predict therapeutic outcomes to ancient genetic programs tied to human evolution. The convergence of anti-inflammatory effects, visual processing changes, and developmental impacts suggests these compounds tap into fundamental brain mechanisms that evolved over millions of years.
Studies in this issue
Primary sources used for this newsletter.
- Magnesium-Ibogaine’s mystical experiences linked to better PTSD symptoms in veteransmain storyJournal of affective disorders2025-11-20PMID 41265656
- Psychedelic-related gene activity linked to serotonin receptors, brain layers, and fast-evolving human DNAkey findingResearch square2025-11-19PMID 41255984
- Psychedelic use during pregnancy may disturb brain growth and behavior in mouse offspringkey findingbioRxiv : the preprint server for biology2025-11-19PMID 41256514
- Negative emotional bias in depression after treatment with psilocybin or escitalopramkey findingTranslational psychiatry2025-11-19PMID 41257994
- Ketamine lowers brain immune cell activity and boosts calming immune cells outside the brain, easing inflammation-related depression-like behavior in micekey findingMolecular psychiatry2025-11-18PMID 41254322
- Using Psychedelics to Help Patients with Severe Consciousness Disorderskey findingAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025-11-20PMID 41261994
- Psilocybin changes how the brain processes visual contextkey findingNature communications2025-11-21PMID 41271688
Continue reading
All Psychedelic Science issuesGet the next Psychedelic Science issue
Seven papers, once a week. Free.